BioCryst reports positive interim data for Phase II gout drug
This article was originally published in Scrip
Executive Summary
BioCryst Pharmaceuticals' oral gout candidate BCX4208 achieved positive interim results in a Phase IIa study, demonstrating a significant reduction of serum uric acid concentration after 21 days of treatment.